throbber
FT-IR and Near-Infared FT-Raman Studies of the Secondary Structure of
`Insulinotropin in the Solid State: a-Helix to @-Sheet Conversion Induced by
`Phenol and/or by High Shear Force
`
`YESOOK KIM'^, CAROL A. ROSE', YONGLIANG L I ~ , YUKIHIRO OZAKI~~, GEETA DATTA*, AND ANTHONY T. Tugx
`Received February 18, 1994, from the *Pharmaceutical Research and Development, Central Research Division, Pfizer, Inc.,
`Groton, CT 06340, #Department of Chemistry, Kwansei Gakuin University, Nishinomiya 662, Japan, and *Department of
`Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523.
`Accepted for publication May 9, 1994@
`
`I
`
`15
`
`10
`
`25
`
`30
`
`5
`
`20
`
`His - Ala - Glu - Gly - Thr - Phe - Thr -
`Ser - Asp - Val - Ser - Ser - Tyr - Leu -
`Glu - Gly - Gln - Ala - Ala - Lys - Glu -
`Phe - Ile - Ala - Trp - Leu - Val - Lys -
`Gly - Arg - Gly
`
`Abstract 0 Insulinotropin (glucagon-like peptide I) is a peptide
`containing 31 amino acid residues. I t stimulates the secretion of the
`hormone insulin. The solubility of this peptide is highly dependent on
`its environment and the treatment that it has undergone. For instance,
`synthetic insulinotropin is highly soluble in neutral phosphate-buffered
`saline (1 mg/ml). However, the application of shear force by stirring
`renders it extremely insoluble (1 hg/mL). This property may be
`explained in terms of a change in peptide secondary structure with
`no alteration in primary structure.
`I n order to understand this
`phenomenon, FT-IR and near-IR FT-Raman were employed to examine
`four samples prepared under different experimental conditions. I t
`was found that solubility decreases as the a-helix is converted to an
`antiparallel &sheet structure.
`
`Introduction
`
`Proteins and peptides are often most soluble under conditions
`mimicking their natural environment. When they are exposed
`to unnatural environments, they tend to form precipitates or
`aggregates as a result of decreasing solubility. The physical basis
`for protein insolubility is still unclear. However, it has been
`proposed that the hydrophobicity of amino acids,14 the primary
`structure, and the peptide backbone conformation7-* all con-
`tribute toward the solubility of the protein. The peptide
`backbone conformation may be indicative of the solubility of
`the protein. Many studies have suggested that protein insolu-
`bility may depend on the content of the p-sheet structure. For
`instance, insulin forms insoluble fibrils when heated in acid.
`Structural studies carried out by Burke and Rougvieg showed
`that the fibrils had a cross-p-structure. It is well-known that a
`@-peptide is a major component of amyloid deposits in Alz-
`heimer's disease.1&l2 Analysis of a protein that was precipitated
`by salting-out also demonstrated a correlation between increased
`&sheet structure and decreased s01ubility.l~
`Glucagon-like peptide I (insulinotropin) is a 31-amino acid
`peptide,lP17 the primary sequence of which is shown in Figure
`1. The solubility of insulinotropin amorphous materials varies
`from 1 mg/mL to 1 hg/mL in neutral pH phosphate-buffered
`saline depending on the method of preparation. For a better
`understanding of what causes the dramatic changes in solubility
`of insulinotropin, characterization of the secondary and tertiary
`structures of these solid materials is essential. FT-IR and Raman
`spectroscopy are the most widely used techniques to characterize
`protein structures in the solid state, especially when the material
`is amorphous, In order to examine the relationship of the p-sheet
`content to solubility, the structure of insulinotropin was studied
`in its highly soluble form and in its insoluble form using FT-IR
`and Raman spectroscopy.
`
`e Abstract published in Advance ACS Abstracts, June 15,1994.
`
`Figure 1-Primary structure of insulinotropin.
`
`Our study showed that the percentage of &sheet conformers
`played a role in determining its solubility in aqueous media.
`
`Experimental Section
`Materials and Methods-Insulinotropin
`(lot #'501713) used through-
`out this study was synthesized by solid-state peptide synthesis and was
`obtained from Pfizer, Inc. Dulbecco's phosphate-buffered saline (PBS)
`was purchased from Gibco (Life Technologies, Inc.). Phenol (fused,
`USP grade) was obtained from J. T. Baker.
`Sample A was the original synthetic insulinotropin, which was readily
`soluble. A 1 mg/mL insulinotropin solution in water for injection was
`stirred vigorously with a magnetic stir bar for 24 h to form aggregates.
`The aggregates were isolated by centrifuging the sample to pellet the
`solids and removing the supernatant. These isolated solids were labeled
`as sample B. For the preparation of sample C, a 2 mg/mL insulinotropin
`solution in PBS and a 4.4 mg/mL phenol solution in PBS were combined
`in a 1:l volume ratio in a glass vial. The vial contents were inverted
`several times to mix the two solutions thoroughly. A precipitate formed
`immediately. However, the vial was sealed and kept at ambient
`temperature for 24 h to ensure complete precipitate formation. The
`precipitates were isolated by centrifuging the sample to pellet the solids
`and removing the supernatant. These isolated solids were labeled as
`sample C. Sample D was prepared in the same manner as sample C
`except that its contents were stirred vigorously for 24 h with a magnetic
`stir bar prior to centrifugation.
`The equilibrium solubility for samples A-D was determined at room
`temperature by dispersing an excess amount of solid into PBS with a
`vortex mixer for approximately 10 s. This dispersion was allowed to sit
`at ambient temperature for 24 h. The dispersion was centrifuged to
`pellet the solids. The supernatant was filtered through a 0.22-pm
`Millipore Millex-GV filter and assayed by HPLC for insulinotropin
`concentration.
`Analytical HPLC assay of insulinotropin was conducted on a Vydac
`Protein C4 column (Rainin Cat# 214TP54). The gradient program used
`for the assay is listed below
`
`time (min)
`Yo A
`%B
`
`0
`75
`25
`
`5
`75
`25
`
`30
`50
`50
`
`35
`50
`50
`
`37
`75
`25
`
`46
`75
`25
`
`where A represents 0.1% trifluoroacetic acid (TFA) in water and B
`represents 0.1 % TFA in acetonitrile. The flow rate was set at 1 mL/min
`
`0 1994, American Chemical Society and
`American Pharmaceutical Association
`
`0022-3549/94/1200- 1 175$04.50/0
`
`Journal of Pharmaceutical Sciences / 1 I75
`Vol. 83, No. 8, August 1994
`
`Novo Nordisk Ex. 2035, P. 1
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`Table 1-Equlllbrlum Solublllty of Samples A-D In pH 7.1
`Phosphate-Buffered Saline
`Samples
`Solubility (mg/mL)
`1
`A
`0.001
`B
`
`Samples
`c
`D
`
`Solubility (mg/mL)
`0.47
`0.001
`
`and the column kept at ambient temperature (25 "C). Detection was
`by UV at 215 nm. Insulinotropin retention time was ca. 23 min.
`The equipment used for the HPLC assay consisted of an LDC Consta-
`Metric 4100 solvent delivery system, a Bio-Rad Model AS-100 HRLC
`automatic sampling system, an LDC SpectroMonitor 4100 programmable
`variable-wavelength detector, and a Spectra-Physics Chrom Jet integra-
`tor.
`Vibrational Spectroscopy-FT-IR spectra of proteins were obtained
`by microinfrared measurements, using an IR-MAU100 unit with a MCT
`detector (IR-DETlO2) attached to a JEOL JIR-6500 FT-IR spectrom-
`eter.'* All the spectra were recorded at a 4-cm-l resolution with 200-
`1000 scans. The proteins were put on a Ge window and crushed to
`obtain satisfactory spectra. The second-derivative spectralg were
`calculated (smoothing points, 13) by using JEOL JIR-6500 FT-IR
`software. The percentage contributions of the a- and @-conformations
`were calculated on the basis of the method of Dong et a1.20 All these
`calculations have been made using the area under the peaks from the
`second-derivative spectrum.
`Near-IR FT-Raman spectra of proteins were measured at an 8-cm-1
`resolution with a JEOL JRS-FT 6500N Raman spectrometer equipped
`with an InGaAs detector.2I The 1064-nm line of a CW NdYAG laser
`(Spectron SL301) was used for excitation, and the laser power employed
`at the sample position was 350-850 mW. Raman scattering light was
`collected with a 180" backscattering geometry, and all the spectra were
`the result of the coaddition of 2000-4000 interferograms.
`Hydrophobicity Analysis-Hydrophobicity analysis of this peptide
`was possible since the primary sequence was known. The Kyte and
`Doolittle scale of hydropathy was used to evaluate the hydrophilic and
`hydrophobic regions of the peptide.22 This method uses a moving-
`segment approach that continuously determines the hydropathy within
`a segment of predetermined length (n) as it advances through the
`sequence from the amino to the carboxy terminus.22 Six is often chosen
`as n, so that the segment length is larger than the oscillations associated
`with the periodic helix or strand and yet sufficient local information is
`retained. For insulinotropin (31-amino acid peptide), an average of
`hydropathy over six residues was calculated up to the 26th residue, and
`then the n was reduced by one each time as the C-terminal was
`approached.
`spectrum was
`Circular Dichroism (CD) Measurements-CD
`recorded on a 5-720 Jasco circular dichroic spectropolarimeter in 0.01-
`cm pathlength cells at 25 "C. The peptide concentration was 0.8 mM
`in a 50 mM phosphate buffer at pH 8.
`Water Content Determination-Water contents in thesolid samples
`were determined by two different methods: coulometric Karl Fisher
`titration23 (Mitsubishi moisture meter, Model CA-06, Mitsubishi Kasei
`Corp., Tokyo, Japan) and thermogravimetric analysis" (TGS-2 analyzer,
`Perkin-Elmer, Norwalk, CT).
`
`Results
`Solubility Behavior-The equilibrium solubility in PBS for
`samples A-D are summarized in Table 1. The solubility of the
`original synthetic insulinotropin (sample A) is 1 mg/mL. If an
`insulinotropin solution in water or PBS is stirred vigorously,
`highly insoluble aggregates are formed. The isolated solids
`(sample B) have a solubility of about 1 pg/mL in PBS. The
`solubility of the phenol precipitate of insulinotropin (sample C)
`is 0.47 mg/mL in PBS. Sample D constitutes the aggregates
`isolated from an insulinotropin solution and a phenol solution
`that were combined and then stirred overnight. This sample
`has a solubility of about 1 pg/mL in PBS.
`Peptide Backbone Analysis by FT-IR-The band assign-
`ments for different conformations are studied by many inves-
`tigators are summarized in Table 2.Z5s26
`
`1176 / Journal of Pharmaceutical Sciences
`Vol. 83, No. 8, August 1994
`
`Table 2-IR Band Assignment of Amlde I and I1 to Dtfferent
`Conformers of Polypeptide Studled by Other Investlgators2s~2a
`Frequency (cm-l)
`Amide I
`Amide 11
`1650- 1655
`15 16-1 546
`1632- 1635
`1530
`1668 (theoretical)
`1685
`1630
`1645
`1685- 1690
`1660
`
`~
`
`1530-1550
`
`Not studied
`Not studied
`
`Conformer
`
`a-Helix
`Antiparallel P-sheet
`
`Parallel @-sheet
`
`@-Turn
`10 Helix or distorted a-helix
`
`WAVENUMBER CM'
`
`-0.0080
`
`1654
`
`FT-IR spectrum of synthetic insulinotropin (sample A). (B)
`Figure 2-(A)
`Second-derivative of sample A.
`
`The FT-IR spectra of the solid insulinotropin samples (A, B,
`C, and D) made under different conditions are shown in Figures
`2A, 3A, 4A, and 5A, respectively, and their frequencies in the
`amide I and 11 regions are summarized in Table 3.
`Instead of relying only on the original FT-IR spectra, the
`second-derivative spectrum of each sample was also obtained
`(Figures ZB, 3B, 4B, and 5B, respectively) since small shoulders
`in the spectrum can be seen as clear peaks in the second-derivative
`spectrum. The area under these peaks can be used to determine
`
`the percentage composition of the various stru~tures.~g~~O The
`contents of different conformers for samples A-D were obtained
`by analyzing Figures ZB, 3B, 4B, and 5B, and are summarized
`in Table 4. The differences in the amide regions of the spectra
`of the four samples are very clear and distinct. The peak at 1654
`cm-1 is strong and distinct only in the spectrum of sample A.
`Sample B shows an increase in intensity of the peak at 1668 and
`1635 cm-l. Sample C has a very intense peak at 1635 cm-l. Sample
`D, on the other hand, has two very intense peaks at 1668 and
`at 1632 cm-'. These clear differences can allow us to draw valid
`conclusions on structural differences among the four samples.
`For sample A, a major peak was observed at 1657 cm-1 (Figure
`2A). This is an indication of an a-helix.
`The corresponding second-derivative spectrum reveals much
`more information (Figure 2B). The main peak is at 1654 cm-1,
`which is an indication of an a-helix (49%). The 1685-cm-1 band,
`shown in the second-derivative spectrum as a small but distinct
`
`Novo Nordisk Ex. 2035, P. 2
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`A
`
`0.2000
`
`0.1500
`
`a
`
`c : 0.100c
`0 3
`
`0.0500
`
`0. 0000
`41
`
`3280 i' \,
`
`j002
`
`Figure 3-(A) FT-IR spectrum of sample B. (B) Secondderivative spectrum
`of sample 8.
`
`0.4000-
`
`A
`
`I 610
`
`I6607
`
`FT-IR spectrum of sample D.
`Figure 5-(A)
`spectrum of sample D.
`Table 3-Frequency Observed for Insullnotropln Samples A-D
`In Amide I and I1 Regions Studied by FT-IR
`Frequency (cm-')
`Amide I1
`Amide I
`1537
`1657
`1635 (major)
`1543
`1668 (minor)
`1630 (major)
`1660 (minor)
`1630 (major)
`1666 (minor)
`
`(B) Secondderivative
`
`1545
`
`1539
`
`Sample
`A
`B
`
`C
`
`D
`
`A h
`
`backbone conformation when insulinotropin is subjected to high
`shear force.
`Sample C is the precipitate formed when an insulinotropin
`solution is combined with phenol solution. The IR spectrum of
`sample C is basically similar to that of sample B with peaks at
`1630 and 1660 cm-I (Figure 4A). The presence of these
`antiparallel &sheet bands is also seen in the second-derivative
`spectrum (Figure 4B). However, in contrast to sample B, a
`Y ,I
`shoulder was observed at 1655 cm-I (Figure 4B). This is an
`1600
`1640
`indication of an a-helix structure, which was quantitated to be
`WAVENUMBER CM'
`FT-IR spectrum of sample C.
`Figure 4-(A)
`21 ?6 of the overall structure.
`spectrum of sample C.
`Sample D was prepared by applying shear force to sample C
`before it was isolated from the mother liquor. The FT-IR
`spectrum of sample D (Figure 5A) is very much like those of
`samples B and C. However, the second-derivative spectrum
`(Figure 5B) is more similar to that of sample B (Figure 3B) than
`sample C (Figure 4B). For sample B, there are two bands in the
`1632-cm-l region, instead of one band as for sample D.
`There are broad bands in the region of 2800-3100 cm-1 in the
`spectra of all samples (Figure 2-5). These bands are constituted
`of C-H stretching vibration, overtones of C-H bending, and
`Fermi resonance bands. The interpretation of these bands would
`be very important, if the samples were lipids or membranes.
`However, no correlation was reported between the secondary
`and tertiary structures of proteins and these bands. Therefore,
`no further analysis was carried out on these bands. The distinct
`
`I
`
`-0.0080
`
`-0.0120 I
`I300
`
`1760
`
`1720
`
`1680
`
`1560
`
`1520
`
`1480
`
`1440
`
`1400
`
`(B) Secondderivative
`
`peak, indicates the presence of a small amount of an antiparallel
`&sheet or &turn.
`Sample B shows dramatic changes in its FT-IR and second-
`derivative spectra as compared to sample A. The a-helix band
`at 1657 cm-1 is no longer visible (0% a-helix). Moreover, the
`amide I band has two peaks at 1635 cm-' (major) and at 1668
`cm-1 (minor) in the FT-IR spectrum (Figure 3A). The second
`derivative spectrum (Figure 3B) also clearly indicates the
`presence of bands at 1635 and 1668 crn-'. Both of the 1635 and
`1668 cm-l bands are indications of an antiparallel p-sheet
`structure. Asmall band at 1645 cm-l is observed in the derivative
`spectrum, but not in the original IR spectrum. The spectra of
`Figure 3A,B clearly signify that there is a dramatic change in the
`
`Journal of Pharmaceutical Sciences / 1177
`Vol. 83, No. 8. August 1994
`
`Novo Nordisk Ex. 2035, P. 3
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`Table 4-Characterlstlc Band Frequencles and the Content of
`Dlfferent Conformers for Insulinotropin Solids Prepared by
`Different Methods
`Sample Frequency (cm-') Conformation Assignment Content (%)
`1654 (very large)
`a-Helix
`A
`49
`Antiparallel /.?-sheet
`1635
`13
`1685 (small)
`Antiparallel @-sheet
`12
`Random coila
`26
`Antiparallel &sheet
`22
`Antiparallel &sheet
`32
`Random coila
`46
`Antiparallel @-sheet or
`49
`parallel &sheet
`a-Helix
`Distorted a-helix or
`antiparallel &sheet
`Random coila
`Antiparallel @-sheet or
`parallel @-sheet
`Antiparallel @-sheet
`27
`Random coila
`34
`aThe content of random coil is calculated from the difference
`between the total content and the summation of a-helix and ,&sheet
`structure contents.
`
`B
`
`C
`
`1635 (large)
`1668 (very large)
`
`1630 (very large)
`
`1655 (shoulder)
`1666 (broad and
`moderate size)
`
`D
`
`1632
`
`1666
`
`21
`37
`
`0
`39
`
`~
`
`peak at 3280-3290 cm-1 is obviously from OH vibration of the
`water molecules present in the sample and the NH vibration of
`the amino groups of the peptide. In all of these samples the
`amide I1 band is very distinct (1539-1545 cm-I). This amide I1
`band is Raman inactive and thus is not seen in the Raman spectra
`(Figure 6).
`spec-
`Near-Infrared FT-Raman Spectroscopy-Raman
`troscopy has been employed extensively for protein conformation
`identification for the last 2 decades. Recently near-infrared FT-
`Raman spectroscopy has been rapidly developed, as it has
`advantages over conventional Raman spectroscopy. Near-
`infrared excitation can avoid fluorescence background and largely
`reduce photodecomposition. Therefore, FT-Raman spectros-
`copy provides Raman spectra with highly accurate frequencies
`with clean background^.^^ For the present study, the amide I
`and I11 regions were examined carefully.28-30
`For the a-helix conformation, the amide I frequency is
`relatively low, ranging from 1642 to 1658 cm-l. The antiparallel
`@-sheet structure is in the higher frequency range of 1662-1680
`cm-l. Frequencies due to random coil structures are between
`the frequencies of the a-helix and @-sheet, i.e., between 1660 and
`1665 cm-1. The amide I11 band of the a-helix appears at 1260-
`1300 cm-1, while that of the random coil has relatively low
`frequencies of 1240-1250 cm-I. For the /3-sheet structure, the
`amide I11 absorbs at 1242-1260 cm-l.
`The original synthetic insulinotropin (sample A) gives a
`distinct amide band at 1659 cm-l, indicating the presence of an
`a-helical conformation (Figure 6A). Although the main peak is
`located at 1659 cm-l, there are shoulders at 1685 and 1695 cm-1.
`This suggests that the secondary structure of sample A consists
`mainly of an a-helix, but some amount of &sheet is also present
`in the native, untreated insulinotropin.
`For the amide I11 region, there are continuous ascending bands
`from 1250 to 1300 cm-1. This region is a highly mixed vibrational
`zone. For an accurate determination of amide I11 bands, it is
`usually recommended to dissolve the protein of interest in D20
`to allow isotopic exchange. The deuterated protein should give
`a new amide 111' band in the vicinity of 980 cm-1, and any bands
`not shifted in the region of 1200-1300 cm-l are not amide I11
`bands.28~29 Isotopic exchange of hydrogen and deuterium atoms
`induced by dissolving sample A in D20 caused these bands to
`disappear and shift to lower frequencies (the spectrum is not
`
`1178 / Journal of Pharmaceutical Sciences
`Vol. 83, No. 8, August 1994
`
`1003
`
`1335
`
`1.2000
`
`0.8000
`
`1659 I
`
`0.4000
`
`0.0000
`
`I666
`I
`
`1870
`
`B
`
`I003
`
`I h
`
`D
`
`0,3200
`
`>
`I- o.2800
`a z
`W
`i- z
`Z a
`2 0.2000
`a
`U
`
`0.2400
`
`0,2400
`
`0,1600
`
`0.1200
`
`0.4000
`
`0.3200
`
`0,2400
`
`0.1600
`
`1700
`
`1600
`
`1500
`
`1300
`I200
`I100
`1400
`WAVENUMBER CM'
`Flgure 6-FT-Raman spectra of insulinotropin in the solid state: (A) sample
`A, (B) sample B, (C) sample C, (D) sample D.
`
`1000
`
`900
`
`BOO
`
`shown). This suggests that the continuous ascending bands in
`1250-1300 cm-' are an expression of an a-helix.
`Due to the low solubility of samples B-D, hydrogen/deuterium
`isotopic exchange could not be carried out. The Raman spectra
`of samples B-D are shown in Figure 6B-D.
`The amide [ bands of sample B-D are quite similar to each
`other: 1666 cm-' for sample B, 1666 cm-l for sample C, and 1670
`cm-' for sample D. This is an indication of an antiparallel &sheet
`structure for these samples. Resolution of the amide I band for
`Raman is not as good as that for FT-IR, but it clearly shows that
`there is a shift of a-helix to 8-sheet structure from sample A to
`sample B-D. The decrease in solubility (Table 1) from sample
`A to samples B-D can be correlated with a major conformation
`change from a-helix to 0-sheet structures.
`The C-H bending vibrational mode is strongly Raman active,
`and an intense Raman band is observed at 1450 cm-1 in all
`samples. However, this band is very weak in the IR spectra
`(Figures 2-5)
`Hydrophobicity Analysis-The hydrophobicity analysis of
`insulinotropin (Figure 7) indicated that the region Ala(lS)-Ala-
`(24) is the most hydrophobic. This hydrophobic region is located
`between two hydrophilic regions, Ser(ll)-Gln(l7) and Trp(25)-
`Gly(31). The His(l)-Val(lO) is neither very hydrophobic nor
`very hydrophilic. These regions would therefore determine the
`
`Novo Nordisk Ex. 2035, P. 4
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`3
`
`2
`
`,
`
`0
`
`
`
`t
`
`0
`
`0
`
`a e
`
`r
`
`”
`
`l
`
`
`
`2
`
`1 2 3 4
`
`5 6
`
`7 8 9 10 1 1 12 13 I 4 15 16 17 18 19 70
`
`22 23 24 25 26 77 78 29 30 1 1
`
`Residue number
`Figure 7-Hydrophobicity of insulinotropin. The values were calculated
`by the Kyte and Doolittle method.**
`
`i IOEiOl
`
`1 WE+U
`
`I SOEtOl
`
`190
`
`ZM
`
`210
`
`x n
`ZIO
`Wwdcnpb (nm)
`
`Z*O
`
`zso
`
`1M
`
`Figure 8-Far-UV CD spectrum of insulinotropin in solution. The peptide
`concentration was 0.8 mM in a 50 mM phosphate buffer at pH 8.
`
`manner in which the peptide would fold under different
`environmental conditions such as solvent, pH, and ionic strength.
`Circular Dichroism-Figure 8 shows the far-UV CD spec-
`trum of insulinotropin in solution. The spectrum is characteristic
`of an a-helical conformation: two minima at 207 and 223 nm
`and a maximum at near 190 nm.31
`Water Content Determination-Sample A was the only dry
`powder, and samples B-D were wet cakes. Water content
`determinations were performed in duplicate for each sample.
`The two methods, thermogravimetric analysis and coulometric
`Karl Fisher titration, showed almost the same results, although
`the former tended to give a little higher (0.3% higher on an
`average) water content values than the latter. The water content
`of sample A was 6.8% w/w, and those of the wet samples (B-D)
`were in the range of 85-87% w/w.
`
`Discussion
`Insulinotropin is composed of 31 amino acid residues. The
`hydrophobicity profile indicates that the highest hydrophobicity
`region lies between Ala(18) and Ala(24). The original synthetic
`insulinotropin (sample A) has a high solubility in aqueous media
`with a high a-helix content, as demonstrated in the CD spectrum
`(Figure 8). It suggests that the Ala(18)--Ala(24) hydrophobic
`region must be buried inside by the molecule and the hydrophilic
`regions must be in the exposed state. We can presume that the
`two hydrophylic regions, Ser(l1)-Gln(l7) and Trp(25)-Gly(31),
`form a-helixes and are in good contact with water molecules.
`Prestrelski et al. reported dehydration-induced conformational
`changes in proteins.32 They observed conformational transitions
`
`from a helical conformation or an unordered structure to a P-sheet
`after freeze-drying protein solutions. Similarly, we observed an
`a-helix to @-sheet transition when the original peptide (sample
`A) in solution was exposed to phenol (sample C) or high shear
`force (samples B and D). Samples A was the only dry powder
`(moisture content = 6.8% w/w), and the other samples (B-D)
`were not subjected to any kind of drying process besides
`centrifugation (moisture contents 2 85% w/w). Therefore, it is
`difficult to relate the cause of the a to @ conversion observed in
`our study to dehydration.
`Ismail et al. demonstrated that certain denaturing conditions
`could cause irreversible intermolecular self-association of a
`peptide that was accompanied by the appearance of a very strong
`IR absorption band at 1618 cm-l.33 Since we have not observed
`such a band in the 1610-1620 cm-l region of the IR spectra for
`any of the insulinotropin samples, it is unlikely that the decreased
`solubility for the precipitated samples is attributed to irreversible
`self-association. The high-shear-induced precipitates (samples
`B and D), which have the lowest solubility in neutral pH range
`(1 jtg/mL solubility in PBS or water), are in fact readily soluble
`in an acidic solvent such as 0.01 N HC1 or 0.1 % trifluoroacetic
`acid in water. We have performed an in vitro bioactivity test34
`with the high-shear-induced precipitates of insulinotropin after
`redissolving them in an acidic solvent. No differences in
`bioactivity were observed between the original peptide (sample
`A) and the precipitated samples, and all of them were fully active.
`The self-association of synthetic insulinotropin in solution
`was characterized by Grucza et al. using equilibrium analytical
`ultracentrifugation and CD spectroscopy.35 It was determined
`that the peptide formed a tetrameric species with significantly
`higher a-helical content than the monomer. They also observed
`that the tetramers precipitated out of the solution upon storage
`at ambient temperature overnight, but the aggregation was
`completely reversible.
`It has been suggested that proteins in solution are destabilized
`by protein adsorption at hydrophobic interfaces (air-water
`interface or water-container materials), and that the initial step
`is nucleation. Partially or completely unfolded protein molecules
`form nuclei which serve as precursors to large aggregates.-O
`Since insulinotropin does not contain any disulfide bonds, the
`peptide may not have a tightly packed three-dimensional
`structure. With shaking or stirring, the air-liquid and the liquid-
`solid interfaces increase, leading to greater conformational
`changes and denaturation. From the results in Table 4, it is
`evident that insulinotropin underwent conformational changes
`when it was subjected to vigorous agitation. For the samples B
`and D, the contents of the @-sheet and random coil increased at
`the expense of the a-helix. The mechanism of this conforma-
`tional conversion is not understood, however. This may not be
`a single event.
`The helix to random coil transition is one of the most
`thoroughly studied phenomena. Interconversion of the two
`structures can occur upon changing the pH, the solvent, the
`temperature, etc., and the transition is very abrupt, indicative
`of a cooperative system.41 However, the mechanism of @-sheet
`formation is not well understood. Synthetic polypeptides that
`form &sheets generally produce large, insoluble structures
`comprising many peptide chains.41 With the limited information
`available, one can propose two separate events occurring.42 At
`first, insulinotropin molecules lose their helical structure and
`become disordered due to the hydrophobic interfaces. Then,
`the disordered chains aggregate, forming a &sheet structure,
`which results in a low solubility in aqueous media. A kinetic
`study is being carried out in our laboratory to elucidate the
`mechanism of this phenomenon.
`When insulinotropin is mixed with phenol without stirring
`(sample C), the solubility is still low (470 jtglmL), but much
`higher than that of samples B and D, which were stirred (1 pg/
`mL). Both IR and Raman spectroscopy provide evidence for
`
`Journal of Pharmaceutical Sciences / 1179
`Vol. 83, No. 8, August 1994
`
`Novo Nordisk Ex. 2035, P. 5
`Mylan Institutional v. Novo Nordisk
`IPR2020-00324
`
`

`

`25. Schellman, J. A.; Schellman, 8. In The Proteins, 2nd ed.; Neurath,
`
`27.
`28.
`
`29.
`
`21. Ozaki, Y.; Cho, R. K.; Ahn, J. J. SPIE Proc. 1992,1921,330-334.
`22. Kyte, J.; Doolittle, R. H. J. Mol. Biol. 1982, 157, 105-132.
`23. Macleod, S . K. Analytical Chemistry 1991, 63, 557-568.
`24. Skoog, D. A. Principles of Instrumental Analysis, 3rded.; Saunders
`College Publishing: Philadel hia, 1985; Chapter 24.
`H. Ed.; Academic Press: 1962, Vol. 2, pp 96-127.
`26. Gorga, J. C.; Dong, A.; Manning, M. C.; Woody, R. W.; Caughey,
`W. S.; Strominger, J. L. Proc. Natl. Acad. Sci. U.S.A. 1989, 86,
`2321-2325.
`Ozaki, Y.; Mizuno, A.; Sato, H.; Kawauchi, K.; Muraishi, S. Appl.
`Spectrosc. 1992,46, 553-536.
`Tu, A. T. Raman Spectroscopy in Biology: Principles and
`Applications; John Wiley & Sons: New York, 1982; pp 66-84.
`Tu, A. T. In Peptide Backbone Conformation and Microenvi-
`ronment of Protein Side Chains in Spectroscopy of Biological
`Systems; Clark, R. J. H.; Hester, R. E., Ed.; John Wiley & Sons:
`New York, 1986; pp 47-112.
`Parker, F. S. Applications of Infrared, Raman and Resonance
`_ _
`Raman Spectroscopy in Biochemistry; Plenum Press: New York.
`- .
`1983; pp 83-153.
`Creighton, T. E. Proteins; W. H. Freeman and Company: New
`Prestrelski; &s. J.; Tedeschi, N.; Arakawa, T.; Carpenter, J. F.
`York. 1984: DD 179-182.
`Biophys. ,I. 1993, 65, 661-671.
`Ismail, A. A.; Mantsch, H. H.; Wong, T. T. Biochim. Biophys. Acta
`1992,1121,183-188.
`Parker, J. C.; Andrews, K. M.; Rescek,D. M.; Massefski, W.; Withka,
`J. M.; Andrews, G. C.; Contillo, L. G.; Singlton, D. H. Manuscript
`in preparation.
`Grucza, R. A.; Emery, M. J., Geoghegan, K. F.; Chrunyk, B. A.
`Manuscript in preparation.
`Sluzky, V.; Tamada, J. A.; Klibanov, A. M.; Langer, R. Proc. Natl.
`Acad. Sci. U.S.A. 1991, 88, 9377-9381.
`Vroman, L.; Adams, A.; Kings, M. Fed. Proc. 1971,30,1494-1502.
`Dathe, M.; Gast, K.; Zirwer, D.; Welfle, H.; Mehlis, B. Int. J. Pept.
`Protein Res. 1990, 36,344-349.
`Thurow, H.; Geisen, K. Diabetologia 1984,27, 212-218.
`Feingold, A.; Jenkins, B.; Kraegen, E. W. Diabetologia 1984,27,
`373-378.
`Creighton, T. E. Proteins; W. H. Freeman and Company: New
`York, 1984; Chapter 5.
`Auer, H. E.; Patton, E. Biophys. Chem. 1976, 4, 15-21.
`
`30.
`
`31.
`
`32.
`
`33.
`34.
`
`35.
`
`36.
`
`37.
`38.
`
`39.
`40.
`41.
`
`42.
`
`Acknowledgments
`We acknowledge the advice given by Dr. Wayne A. Boettner for the
`preparation of this manuscript. We thank Dr. Cheryl M. Kirkman for
`the HPLC method development of insulinotropin and Mr. Geoffrey
`Stamper for the CD measurement.
`
`the significant decrease in the a-helix content in sample C with
`respect to sample A. This sensitivity of the helix to phenol may
`indicate that a certain component, such as a specific amino acid
`residue that is important in the maintenance of the helical
`structure, can be easily disrupted by phenol, possibly by the OH
`group.
`In this study of insulinotropin, the relationship between
`solubility and peptide backbone conformation is demonstrated
`by vibrational spectroscopic evidence. Specifically, the decrease
`in a-helix content is definitely related to the decrease in solubility
`of insulinotropin.
`
`References and Notes
`1. Rose, G. D.; Geselowitz, A. R.; Lesser, G. J.; Lee, R. H.; Zehfus, M.
`H. Science 1985,229,834-838.
`2. Nozaki. Y.: Tanford, C. J. Bcol. Chem. 1971.246. 2211-2217.
`3. Wolfenden. R. Science 1983. 222. 1087-1093.
`4. Meirovitch; H.; Rackovsky, 8.; Scheraga, H. A. Macromolecules
`1980,13, 1398-1405.
`5. Chothia, C. J. Mol. Biol. 1976, 105, 1-12.
`6. Janin, J. Nature (London) 1979,227,491-492.
`7. Narita. M.: Ishikawa. K.: Chen. J.-Y.. Kim, Y. Int. J. Pept. Protein
`Res. 1984,24, 580-587. '
`8. Stryer, L. Biochemistry, 3rd ed.; W. H. Freeman and Company:
`New York, 1988; pp 29-30.
`9. Burk, M. J.; Rougvie, M. A. Biochemistry 1972,1I, 2435-2439.
`10. Zagorski, M. G.; Barrow, C. J. Biochemistry 1992,31,5621-5631.
`11. Lansbury, P. T., Jr. Biochemistry 1992, 31,6865-6870.
`12. Glenner, G. G.; Eanes, M. D. E. D.; Wiley, C. A. Biochem. Biophys.
`Res. Commun. 1988,155, 608-614.
`13. Przybycien, T. M.; Bailey, J. E. Biochim. Biophys. Acta 1989,995,
`-- - -
`281 -245
`14. Bell, G. I.; Sanchez-Pescador, R.; Laybourn, P. J.; Najarian, R. C.
`Natur (London) 1983,302,716-718.
`15. Weir. G. C.: Moisov. S.: Hendrick. G. K.: Habener. J. F. Diabetes
`1989.'38. 338-342.
`16. Lopez, L,-C.; Frazier, M. L.; Su, C. J.; Humar, A.; Sanders, G. F.
`Proc. Natl. Acad. Sci., U.S.A. 1983,80, 5485-5489.
`17. Seino, S.; Welsh, M.; Bell, G. I.; Steiner, F. FEBSLett. 1986,203,
`-- --.
`35-2n
`18. Okeda, K.; Ozaki, Y.; Kawauchi, K.; Muraishi, S. Appl. Spectrosc.
`1990,44,1412-1414.
`19. Susi, H.; Byler, D. M. Biochem. Biophys. Res. Commun. 1

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket